Q1 2023 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Financial performance
Immunology
Cosentyx® - IL-17A inhibitor
Conclusions
Appendix
Innovation: Clinical trials
Neuroscience
Oncology
Indication
NCT05767034 REPLENISH (CAIN457C22301)
Polymyalgia rheumatica
Phase
Phase 3
Patients
360
Primary
Proportion of participants achieving sustained remission
Outcome
Measures
Arms
Intervention
Arm 1 Experimental: Secukinumab 300 mg, randomized in 1:1:1 ratio every
weeks
4
Arm 2 Experimental: Secukinumab 150 mg, randomized in 1:1:1 ratio every 4
weeks
Arm 3 Placebo: randomized in 1:1:1 ratio every 4 weeks
Adult patients with PMR who have recently relapsed
Target
Patients
Readout
Milestone(s)
2025
Publication
TBD
References
Abbreviations
Other
56 Investor Relations | Q1 2023 Results
NOVARTIS | Reimagining MedicineView entire presentation